Your browser is no longer supported. Please, upgrade your browser.
Settings
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E183.87 EPS (ttm)0.16 Insider Own2.70% Shs Outstand1.01B Perf Week-4.62%
Market Cap28.77B Forward P/E6.02 EPS next Y4.74 Insider Trans0.00% Shs Float913.43M Perf Month-10.18%
Income68.00M PEG64.93 EPS next Q1.14 Inst Own59.20% Short Float2.48% Perf Quarter-20.28%
Sales21.90B P/S1.31 EPS this Y-96.10% Inst Trans-6.84% Short Ratio3.26 Perf Half Y-25.22%
Book/sh29.92 P/B0.95 EPS next Y-1.46% ROA0.10% Target Price37.05 Perf Year-44.76%
Cash/sh0.90 P/C31.55 EPS next 5Y2.83% ROE0.30% 52W Range28.06 - 56.44 Perf YTD-21.38%
Dividend1.36 P/FCF14.06 EPS past 5Y-53.00% ROI1.10% 52W High-49.50% Beta0.51
Dividend %4.77% Quick Ratio0.60 Sales past 5Y3.60% Gross Margin54.10% 52W Low1.57% ATR0.83
Employees56960 Current Ratio0.90 Sales Q/Q17.00% Oper. Margin8.60% RSI (14)30.36 Volatility2.53% 2.78%
OptionableYes Debt/Eq1.14 EPS Q/Q-8.00% Profit Margin0.40% Rel Volume0.90 Prev Close28.71
ShortableYes LT Debt/Eq1.08 EarningsMay 11 BMO Payout- Avg Volume6.94M Price28.50
Recom2.50 SMA20-7.32% SMA50-9.89% SMA200-26.13% Volume6,214,520 Change-0.73%
Feb-28-17Downgrade Argus Buy → Hold
Feb-13-17Reiterated Maxim Group Hold $41 → $40
Feb-10-17Downgrade Mizuho Buy → Neutral $40 → $27
Jan-31-17Upgrade BofA/Merrill Neutral → Buy
Jan-31-17Reiterated Barclays Equal Weight $46 → $38
Jan-20-17Downgrade JP Morgan Overweight → Neutral
Jan-09-17Downgrade Wells Fargo Outperform → Market Perform
Jan-06-17Downgrade Maxim Group Buy → Hold $49 → $41
Jan-03-17Reiterated Maxim Group Buy $52 → $49
Dec-07-16Resumed Oppenheimer Outperform
Nov-16-16Reiterated RBC Capital Mkts Outperform $58 → $51
Nov-16-16Reiterated Mizuho Neutral $45 → $40
Nov-16-16Reiterated Maxim Group Buy $72 → $52
Nov-16-16Reiterated Deutsche Bank Buy $68 → $54
Nov-16-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-16-16Downgrade Jefferies Buy → Hold $69 → $40
Nov-14-16Resumed Barclays Equal Weight $46
Nov-14-16Reiterated RBC Capital Mkts Outperform $71 → $58
Nov-07-16Downgrade BofA/Merrill Buy → Neutral
Nov-04-16Downgrade HSBC Securities Buy → Hold
May-26-17 03:02PM  3 Top Dividend Stocks in Generic Drugs Motley Fool
02:00PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-25-17 04:10PM  Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts Investor's Business Daily
04:04PM  How Teva Is Fighting (and Losing) the Big Pharma Battle Investopedia
09:45AM  Major Pharma Short Interest Surges 24/7 Wall St.
May-24-17 07:00PM  Cramer Remix: The market is not ready for this Trump scen... CNBC Videos
04:21PM  Did Neurocrine Just Leave The Door Open For Teva In Tourette's? Investor's Business Daily
10:37AM  Neupogen and Enbrel Could See Falling Revenues in 2017 Market Realist
08:00AM  Today's Research Reports on Stocks to Watch: Teva and Cerus Corporation Accesswire
May-23-17 04:23PM  Teva Reaches New Lows Will It Bottom Out? Investopedia
May-22-17 12:25PM  It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date Benzinga
08:27AM  3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter Motley Fool
May-19-17 01:33PM  Valeant Pharmaceuticals: IntriguedReally? Barrons.com
09:48AM  Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA Zacks
07:30AM  Vetr Issues Strong Buy As Teva Trends Down Benzinga
May-18-17 09:53AM  Teva Pharmaceutical Leaning Towards Foreigner as New CEO TheStreet.com
07:42AM  Teva Pharmaceutical's search committee recommends foreign CEO: report Reuters
07:37AM  Teva Pharmaceutical's search committee recommends foreign CEO -report Reuters
May-17-17 09:00AM  Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference Business Wire
08:00AM  Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting Business Wire
May-16-17 09:54AM  Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka Zacks
May-15-17 07:06PM  Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint Zacks
05:59PM  John Paulson Takes A Shine To Telecom The Wall Street Journal
01:20PM  Teva Announces Launch of Generic Glumetza® in the United States Business Wire
08:00AM  Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125) Business Wire
07:09AM  Biostime International Holdings Limited -- Moody's: Biostime's ratings unaffected by disclosure of PGT option in collaboration agreement with Swisse Moody's
May-12-17 04:20PM  Can Teva Hold Its Own In Bringing Migraine Drugs To Market? Investor's Business Daily
10:26AM  Here's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets Motley Fool
08:00AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceuticals and Merck & Co. Accesswire
07:34AM  Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls Zacks
12:19AM  [$$] Investors Are Losing Patience With Teva The Wall Street Journal
May-11-17 04:17PM  [$$] Investors Are Losing Patience With Teva The Wall Street Journal
04:04PM  Teva Pharma Q1 Sales Lag As Key Multiple Sclerosis Drug Topples Investor's Business Daily
02:30PM  TEVA's Every Narrowing Margin for Error Investopedia
12:07PM  Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers TheStreet.com
11:43AM  Actavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher Motley Fool
11:27AM  Market Overly Negative on Teva Morningstar
09:46AM  Teva Q1 profit tops estimates, revenue up on Actavis deal Reuters
08:39AM  Teva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up Zacks
07:54AM  Early movers: STRP, SNAP, FOXA, WFM, KSS, TEVA, YUM & more CNBC
07:30AM  Teva to Sell Assets Such as Women's Health Unit to Cut Debt Bloomberg
07:23AM  Market Recon: Snapchat Is Down Sharply; Yet, I Am Not Tempted TheStreet.com
07:17AM  Teva stock rises 1.6% after Q1 profit beat, revenue miss MarketWatch
07:16AM  Teva Pharm Q1 profit tops estimates, revenue rises Reuters
07:00AM  Teva Reports First Quarter 2017 Financial Results Business Wire
May-10-17 04:52PM  4 Pressing Questions We Want Answered When Teva Pharmaceutical Reports Tomorrow Morning Motley Fool
09:00AM  Short Interest in Major Pharma Shrinks 24/7 Wall St.
May-09-17 02:22PM  Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings? Zacks
May-08-17 09:26AM  Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards? Zacks
May-05-17 02:00PM  Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint Business Wire
08:00AM  Teva Announces Publication of COPAXONE® (glatiramer acetate injection) Pregnancy Data in the International Journal of MS Care Business Wire
07:00AM  Generic Drug Industry Headwinds Lead to Moat Downgrades Morningstar
May-04-17 08:23AM  Generic Drugmakers Tumble as Perrigo Discloses DoJ Search Zacks
May-03-17 08:53AM  Perrigo Stock Sliding on DOJ Search TheStreet.com
08:32AM  3 Reasons Teva Pharmaceutical Industries Lost Another $520 Million in Market Value in April Motley Fool
May-01-17 02:08PM  Teva Pharmaceutical Is Ready for a Tradable Rally TheStreet.com
Apr-28-17 10:21AM  Teva Pharmaceutical Is Looking to Deal, and That's a Good Thing Motley Fool
Apr-27-17 08:00AM  Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia Business Wire
Apr-26-17 05:08PM  Merck cholesterol drug Vytorin faces competition from Impax, Teva generics Reuters
04:09PM  Teva Announces Launch of Generic Vytorin® in the United States Business Wire
01:12PM  Teva Confirms CFO Is Leaving TheStreet.com
10:12AM  Finance chief quits drugmaker Teva, leaving another gap at top Reuters
09:02AM  Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer Business Wire
08:25AM  Short Sellers Cant Make Up Their Minds on Major Pharma 24/7 Wall St.
07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics Accesswire
06:05AM  Teva Said to Consider Sale of Cancer Portfolio to Reduce Debt Bloomberg
Apr-25-17 04:04PM  Express Scripts, Teva Pharmaceuticals Drop into Tuesdays 52-Week Low Club 24/7 Wall St.
03:08PM  Teva Pharmaceutical CFO Stepping Down TheStreet.com
02:06PM  Teva Pharmaceutical CFO to step down: media Reuters
01:44PM  Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates Benzinga
07:23AM  Teva looks to resume some production at Rimsa plant in Mexico Reuters
Apr-22-17 12:03PM  3 Dividend Stocks That Retirees Should Avoid Motley Fool
Apr-20-17 06:43PM  Teva's new asthma inhaler poses first competition for GSK's Advair Reuters
01:34PM  Teva launches copy of asthma inhaler Advair Reuters
08:42AM  Teva Launches AirDuo RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol Business Wire
Apr-19-17 08:00AM  Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology Business Wire
07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals Accesswire
Apr-18-17 07:11AM  The Billionaire And The Drug Price-Fixing Scandal Forbes
Apr-13-17 09:58AM  U.S. FDA raises concerns over Teva's plant in China Reuters
Apr-12-17 04:54PM  Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops Investor's Business Daily
04:04PM  Cenovus  Energy, DryShips Dip into Wednesdays 52-Week Low Club 24/7 Wall St.
01:40PM  Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva Benzinga
12:57PM  Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside Benzinga
12:43PM  Why Neurocrine Biosciences Stock Is Soaring Higher Today Motley Fool
Apr-10-17 07:18PM  What Will Make Man Smarter? GuruFocus.com
Apr-07-17 03:19PM  Teva Pharmaceutical Said to Be Exploring Sale of Women's Health Unit TheStreet.com
Apr-06-17 08:30AM  Teva to Report First Quarter 2017 Financial Results on May 11, 2017 Business Wire
Apr-05-17 03:36PM  Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst Zacks
09:20AM  History Comes Back to Haunt Teva Pharmaceutical Industries, Sending Shares Down 8% in March Motley Fool
08:47AM  Why Teva stock isnt moving on its major Huntingtons disease drug approval MarketWatch
07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Neurocrine Biosciences Accesswire
07:24AM  An Israeli pharma firm has found a way to make drugs longer lasting and more effective Quartz
07:13AM  [$$] Teva Gets Good News but Still Needs a Head Barrons.com
12:26AM  [$$] Teva: Starting to Pierce the Gloom The Wall Street Journal
Apr-04-17 05:32PM  3 Stocks That Give Us Heartburn Motley Fool
04:36PM  Teva Pharma, Neurocrine Do Battle Over Neurological Treatments Investor's Business Daily
03:19PM  Huge Royals logo takes three strikes but wins approval in OP
12:35PM  [$$] Teva: Starting to Pierce the Gloom
11:44AM  Teva Pharmaceutical Receives FDA Approval For Huntington's Drug
10:39AM  Teva's Huntington's disease drug approved Monday, second drug ever approved for chorea
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the women's health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.